Canopy Growth Corp(CGC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 7:39 PM ET (Korea 10/30 08:39)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.45 | Insider Own | 0.56% | Shs Outstand | 423.0M | Perf Week | 1.46% |
| Market Cap | 0.28B | Forward P/E | - | EPS next Y | 18.4% | Insider Trans | -12.4% | Shs Float | 417.2M | Perf Month | -24.68% |
| Enterprise Value | 0.24B | PEG | - | EPS next Q | -0.03 | Inst Own | 7.86% | Short Float | 7.58% | Perf Quarter | -26.41% |
| Income | -0.17B | P/S | 1.33 | EPS this Y | 83.53% | Inst Trans | -0.01% | Short Ratio | 10.92 | Perf Half Y | -39.19% |
| Sales | 0.21B | P/B | 0.59 | EPS next 5Y | 52.69% | ROA | -23.51% | Short Interest | 31.64M | Perf YTD | -40.79% |
| Book/sh | 1.15 | P/C | 1.18 | EPS past 3/5Y | 77.14% 55.23% | ROE | -40.16% | 52W High | -71.64% ($2.38) | Perf Year | -46% |
| Cash/sh | 0.57 | P/FCF | - | Sales past 3/5Y | -6.5% -13.01% | ROIC | -26.05% | 52W Low | 3.85% ($0.65) | Perf 3Y | -86.68% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 85.06% | Gross Margin | 18.25% | Volatility(W/M) | 4.12% 5.54% | Perf 5Y | -99.47% |
| Dividend TTM | - | EV/Sales | 1.12 | Sales Y/Y TTM | 7.81% | Oper. Margin | -25.43% | ATR (14) | 0.04 | Perf 10Y | -98.56% |
| Dividend Ex-Date | - | Quick Ratio | 2.39 | EPS Q/Q | 84.36% | Profit Margin | -79.75% | RSI (14) | 27.13 | Recom | 2.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.04 | Sales Q/Q | 12.55% | SMA20 | -10.19% ($0.76) | Beta | 0.84 | Target Price | $1.53 |
| Payout | - | Debt/Eq | 0.4 | Earnings | 2026/11/6 | SMA50 | -23.19% ($0.89) | Rel Volume | 0.39 | Prev Close | $0.67 |
| Employees | 1128 | LT Debt/Eq | 0.34 | EPS/Sales Surpr. | 49.05% -1.33% | SMA200 | -32.69% ($1.01) | Avg Volume(3M) | 2.90M | Price | $0.68 |
| IPO | 2014/4/7 | Option/Short | Yes/Yes | Trades | 1871 | Volume | 1,131,833 | Change | 0.46% |
🌿 A Canada-based global cannabis company operating a diversified business spanning Canadian adult-use and medical cannabis, international cannabis, vaporizers (Storz & Bickel), and skincare (This Works). It pursues differentiation by focusing on value-added products such as infused pre-rolls and all-in-one vapes in the adult-use cannabis market.
Over the past 1 year, on the lower side
71% below its 1-year high.
Traded less than usual. That is 39% of its average volume.
Next earnings report: November 6
7 days to go.
CGC has a sound balance sheet but weak earning power
Of every $100 in sales, $25.43 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +83.5% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $133. Peers typically go for $157.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 7.9%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #45 of 83 in the industry
Based on market cap of $283M.
ANIK#44 Anika Therapeutics Inc $292M PER - CGC#45 Canopy Growth Corp $283M PER - 
BIOA#46 BioAge Labs Inc $273M PER - 
ACB#47 Aurora Cannabis Inc $268M PER - 
LFCR#48 Lifecore Biomedical Inc $247M PER - 
FAQ
What kind of company is CGC?
CGC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of CGC?
The market cap of CGC is approximately $283M, ranking 3,715 within its sector.
What is the 52-week high and low for CGC?
CGC has recorded a 52-week high of $2.38 and a low of $0.65.
